Veracyte, Inc.

Health Care
Medical Specialities
www.veracyte.com

Moat Score

Market Cap $3.36B
PE -362
Debt $NaN
Cash $275.16M
EV $NaN
FCF $56.48M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$9.27M
EBIT	-$8.17M
ROE	-1%
ROA	-1%
FCF	$56.48M
Equity	$1.18B
Growth Stability	1
PE	-362.39
PB	2.86
P/FCF	59.46
P/S	7.9
Price/Cash	0.08
Net Margins	6%
Op. Margins	-2%
Sales Growth YoY	29%
Sales Growth QoQ	1%
Sales CAGR	29%
FCF CAGR	0%
Equity CAGR	59%
Earnings Growth YoY	-151%

Earnings Growth QoQ	164%
Sales CAGR 5Y	38%
FCF CAGR 5Y	6%
Equity CAGR 5Y	37%
Earnings CAGR 3Y	24%
Sales CAGR 3Y	24%
FCF CAGR 3Y	99%
Equity CAGR 3Y	2%
Market Cap	$3.36B
Revenue	$425.33M
Assets	$1.28B
Cash	$275.16M
Shares Outstanding	76.11M
Moat Score	35%
Working Capital	286.54M
Current Ratio	5.08
Shares Growth 3y	3%
Equity Growth QoQ	4%
Equity Growth YoY	12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product.

SEC Filings

Direct access to Veracyte, Inc. (VCYT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Veracyte, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Veracyte, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Veracyte, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Veracyte, Inc..

Years

Calculation mode

= $575M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$56M	$57M	$57M	$57M	$57M	$57M	$57M	$58M	$58M	$58M	$58M	$581M
DCF		$51M	$47M	$43M	$39M	$36M	$32M	$30M	$27M	$25M	$22M	$224M
Value	$575M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-77%	-68%	-48%	-43%	-25%	-10%	-30%	-34%	-12%	-21%	6%
ROA	-	-44%	-29%	-34%	-18%	-5%	-8%	-7%	-3%	-7%	-1%
ROE	-	-66%	-53%	-83%	-29%	-5%	-8%	-7%	-3%	-7%	-1%

Bad Net Margins (5.82%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.15	-0.77	-0.97	-1.64	-0.12	-0.06	-0.03	-0	-	-
Debt over Equity	0.12	0.1	0.42	0.67	0.32	0	0	0	0	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	30%	31%	11%	28%	31%	-2%	87%	35%	22%	38%
Earnings YoY growth	-	15%	-7%	-1%	-26%	-45%	177%	116%	-52%	104%	-
Equity YoY growth	-	24%	16%	-38%	114%	200%	76%	160%	-2%	-3%	37%
FCF YoY growth	-	12%	-3%	-20%	-40%	-61%	110%	195%	-97%	-3K%	6%